Akso Health Group (AHG) Financial Statements
Akso Health Group (AHG) reported trailing twelve-month revenue of $13.8M (down 6.4% year on year) and net income of -$18.7M, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$12.8M.
Source: SEC EDGAR filings · read by EquiReason
AHGAkso Health GroupFollow AHG — free
—
Price chart with a free account
- Market cap
- 1.1B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- —
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters.
| Line | FY2019 Mar 19 | FY2020 Mar 20 | FY2021 Mar 21 | FY2022 Mar 22 | FY2023 Mar 23 | FY2024 Mar 24 | FY2025 Mar 25 | FY2026 Mar 26 | TTM | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.6 | 7.0 | 1.8 | 6.0 | 13.2 | 2.4 | 14.8 | 13.8 | — | |
| Gross profit | — | 6.9 | 1.8 | 0.6 | 1.3 | 0.1 | -0.3 | -0.0 | — | |
| Research & development | 0.0 | 0.1 | 0.4 | 0.4 | — | — | — | — | — | |
| Operating income | -7.2 | -48.1 | -4.2 | -3.3 | -14.3 | -8.6 | -166.3 | -20.7 | — | |
| Pre-tax income | -6.8 | -46.9 | -4.3 | -4.0 | -13.1 | -9.1 | -166.3 | -20.7 | — | |
| Income tax | 0.8 | 0.5 | 0.5 | 0.1 | 0.0 | 0.0 | -30.8 | -2.0 | — | |
| Net income | 5.5 | -71.2 | -34.8 | -16.9 | -1.4 | -9.5 | -135.0 | -18.7 | — | |
| Diluted EPS ($) | 0.10 | -1.46 | -0.71 | -0.28 | -0.02 | -0.07 | -0.16 | 0.01 | — | |
| Diluted shares (mn) | 52.9 | 48.8 | 48.8 | 59.6 | 68.6 | 141.5 | 855.3 | 2168.1 | — |
USD millions · SEC XBRL
Akso Health Group — questions
- What is Akso Health Group's revenue?
- $13.8M over the twelve months to the latest filing, down 6.4% year on year, from its 10-Q and 10-K filings.
- What is Akso Health Group's net income?
- -$18.7M over the twelve months to .
- What is Akso Health Group's free cash flow?
- -$12.8M over the twelve months to .
Every figure on this page comes from Akso Health Group's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.